# Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064

> **NCT03918980** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 185 (actual)

## Conditions studied

- Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis

## Interventions

- **DRUG:** LOU064
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03918980
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-18
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03918980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03918980, "Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03918980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*